Close Menu

This story has been updated from a previous version to include information about JP Morgan initiating coverage of Adaptive Biotechnologies.

NEW YORK – Cowen and William Blair today initiated coverage of Adaptive Biotechnologies, both with Outperform ratings.

JP Morgan also initiated coverage with an Overweight rating and provided a price target of $45 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.